Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers
CONCLUSION: RDT has the potential to restore RAI avidity and induce RECIST responses following I-131 therapy in select patients with RAIR-DTC, particularly those with RAS-driven 'follicular' phenotypes. In patients with PTC, none of the evaluated clinical outcomes differed statistically between the redifferentiated and non-redifferentiated subgroups. Further studies are needed to better characterize the long-term survival and/or safety outcomes of high-dose RAI following RDT, particularly whether it could be associated with histologic anaplastic transformation.PMID:37917101 | DOI:10.1089/thy.2023.0456 (Source: Thyroid : of...
Source: Thyroid : official journal of the American Thyroid Association - November 2, 2023 Category: Endocrinology Authors: David Toro-Tobon John C Morris Crystal R Hilger Candy Peskey Jolanta M Durski Mabel Ryder Source Type: research

A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears after Radioactive Iodine Treatment for Thyroid Cancer
CONCLUSIONS: I-131 is present in the tears following RAI therapy for thyroid carcinoma. Frequent PFATs starting on the day of RAI ingestion may decrease the level of I-131 in the tears. This finding could have implications for lowering the risk of NLDO. Future multi-center clinical trials are needed to determine if the use of artificial tears after RAI therapy may decrease the risk of NLDO.CLINICAL TRIAL REGISTRATION: NCT04327999.PMID:37917111 | DOI:10.1089/thy.2023.0338 (Source: Thyroid : official journal of the American Thyroid Association)
Source: Thyroid : official journal of the American Thyroid Association - November 2, 2023 Category: Endocrinology Authors: Irene Lee Jared V Grice Xiangyu Ji Qingxia Chen Lindsay Bischoff Aaron C Jessop Behin Barahimi Francois Codere Louise Mawn Rachel K Sobel Source Type: research

Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers
CONCLUSION: RDT has the potential to restore RAI avidity and induce RECIST responses following I-131 therapy in select patients with RAIR-DTC, particularly those with RAS-driven 'follicular' phenotypes. In patients with PTC, none of the evaluated clinical outcomes differed statistically between the redifferentiated and non-redifferentiated subgroups. Further studies are needed to better characterize the long-term survival and/or safety outcomes of high-dose RAI following RDT, particularly whether it could be associated with histologic anaplastic transformation.PMID:37917101 | DOI:10.1089/thy.2023.0456 (Source: Thyroid : of...
Source: Thyroid : official journal of the American Thyroid Association - November 2, 2023 Category: Endocrinology Authors: David Toro-Tobon John C Morris Crystal R Hilger Candy Peskey Jolanta M Durski Mabel Ryder Source Type: research

A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears after Radioactive Iodine Treatment for Thyroid Cancer
CONCLUSIONS: I-131 is present in the tears following RAI therapy for thyroid carcinoma. Frequent PFATs starting on the day of RAI ingestion may decrease the level of I-131 in the tears. This finding could have implications for lowering the risk of NLDO. Future multi-center clinical trials are needed to determine if the use of artificial tears after RAI therapy may decrease the risk of NLDO.CLINICAL TRIAL REGISTRATION: NCT04327999.PMID:37917111 | DOI:10.1089/thy.2023.0338 (Source: Thyroid : official journal of the American Thyroid Association)
Source: Thyroid : official journal of the American Thyroid Association - November 2, 2023 Category: Endocrinology Authors: Irene Lee Jared V Grice Xiangyu Ji Qingxia Chen Lindsay Bischoff Aaron C Jessop Behin Barahimi Francois Codere Louise Mawn Rachel K Sobel Source Type: research